ASCO June 2nd-June 6th
Education Session
Primary Track: Hematologic Malignancies
Broadening Access to Novel Multiple Myeloma Therapeutics: We Must Do Better
Chair: Surbhi Sidana, MD | Stanford University
Oral Abstract Sessions
Abstract 7001:
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
Gregory Roloff, Rawan Faramand, Ibrahim Aldoss, Noam Kopmar, Marc Schwartz, Simone Dekker, Chenyu Lin, Sean Tracy, Santiago Mercadal Vilchez, Kaitlyn Dykes, Timothy O'Connor, Mohamed Ahmed, Vishal Gupta, Abdullah Ladha, Stephanie Tsai, Jessica Leonard, Ahmed Galal, Ryan Cassaday, Bijal Shah, Lori Muffly
https://meetings.asco.org/abstracts-presentations/219909
Abstract 7008:
Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.
Lori Muffly, Kate Miller, Frances Maguire, Qian Li, Helen Parsons, Theresa Keegan
https://meetings.asco.org/abstracts-presentations/219859
Clinical Science Symposiums
Abstract LBA106:
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
Binod Dhakal, Kwee Yong, Simon Harrison, Maria-Victoria Mateos, Philippe Moreau, Niels van de Donk, Surbhi Sidana, Rakesh Popat, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan Schecter, Katherine Li, Enrique Zudaire, Ying Chen, Jane Gilbert, Lida Bubuteishvili-Pacaud, Nitin Patel, Jesús San-Miguel, Hermann Einsele
https://meetings.asco.org/abstracts-presentations/220015
Abstract LBA107:
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.
Jason Westin, Olalekan Oluwole, Marie Kersten, David Miklos, Miguel-Angel Perales, Armin Ghobadi, Aaron Rapoport, Anna Sureda, Caron Jacobson, Umar Farooq, Tom van Meerten, Matthew Ulrickson, Mahmoud Elsawy, Lori Leslie, Sridhar Chaganti, Michael Dickinson, Yin Yang, Marco Schupp, Christina To, Frederick Locke
https://meetings.asco.org/abstracts-presentations/220014
Posters
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
Frederick Locke, Lazaros Lekakis, Herbert Eradat, Javier Munoz, Michael Tees, Sven de Vos, Rajneesh Nath, Don Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan Oluwole, Miguel-Angel Perales, David Miklos, Paul Fisher, Lovely Goyal, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Neelapu
https://meetings.asco.org/abstracts-presentations/222697
Abstract 7509; Poster Bd #60:
Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Caron Jacobson, Michael Hemmer, Zhen-Huan Hu, Matthew Frank, Leslie Popplewell, Nausheen Ahmed, Yi Lin, Timothy Best, Sara Beygi, Harry Miao, Christine Fu, Fang Sun, Hairong Xu, Marcelo Pasquini
https://meetings.asco.org/abstracts-presentations/218280
Abstract 7571; Poster Bd #122:
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Laura Samples, Hossein Sadrzadeh, Matthew Frigault, Caron Jacobson, Mehdi Hamadani, Ashwath Gurumurthi, Paolo Strati, Roni Shouval, Peter Riedell, Saurabh Dahiya, Jean Yared, Michael Jain, Frederick Locke, Lori Leslie, Narendranath Epperla, Monalisa Ghosh, Alan Skarbnik, Brian Hill, Manali Kamdar, Mazyar Shadman
https://meetings.asco.org/abstracts-presentations/220361
Abstract 8012; Poster Bd #4:
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Doris Hansen, Krina Patel, Lauren Peres, Mehmet Kocoglu, Leyla Shune, Gary Simmons, Christopher Ferreri, Shebli Atrash, Ricardo Parrondo, Saurabh Chhabra, Patrick Costello, Shonali Midha, Melissa Alsina, Peter Voorhees, Myo Htut, Douglas Sborov, Jack Khouri, Murali Janakiram, Yi Lin, Surbhi Sidana
https://meetings.asco.org/abstracts-presentations/219990
Abstract 8011; Poster Bd #3:
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Niels van de Donk, Philippe Moreau, Alfred Garfall, Manisha Bhutani, Albert Oriol, Ajay Nooka, Thomas Martin, Laura Rosiñol, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, Surbhi Sidana
https://meetings.asco.org/abstracts-presentations/220069
Abstract 8011; Poster Bd #5:
Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
Aimaz Afrough, Hamza Hashmi, Doris Hansen, Surbhi Sidana, Chul Ahn, Danai Dima, Ciara Freeman, Omar Alexis Castaneda Puglianini, Mehmet Kocoglu, Shebli Atrash, Peter Voorhees, Leyla Shune, Gary Simmons, Douglas Sborov, Christopher Ferreri, Charlotte Wagner, Krina Patel, Jack Khouri, Larry Anderson, Jr, Yi Lin